# US 2021/0008136 A1 · Improved Oncolytic Reovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0008136 A1
- Document ID: US20210008136A1
- Status: Published application
- Kind: A1
- Application number: 16/979,458
- Filed: 2019-03-13
- Published: 2021-01-14
- Earliest claimed: 2019-03-13
- Applicants: The Governors of the University of Alberta
- Inventors: Maya Shmulevitz; Adil Mohamed; Mary Hitt; Wan Kong Yip
- Web page: https://patentgrep.com/patent/US20210008136A1

## CPC

- A61K 35/765: Reovirus; Rotavirus
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2720/12221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/12222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.

## Claims

### Claim 1

A reovirus genetically modified to express at least one protein from the reovirus T3DPL, wherein the protein is:
T3DPL σ3, T3DPL μ2, or T3DPL λ1.

### Claim 2 (depends on 1)

The reovirus of claim 1, wherein the reovirus expresses T3DPL σ3.

### Claim 3 (depends on 1, 2)

The reovirus of claim 1 or claim 2, wherein the reovirus expresses T3DPL μ2.

### Claim 4

The reovirus of any one of the preceding claims, wherein the reovirus expresses T3DPL λ1.

### Claim 5

The reovirus of any one of the preceding claims, wherein the reovirus is a T3D strain other than T3DPL.

### Claim 6

The reovirus of any one of the preceding claims, wherein the reovirus is T3DTD strain.

### Claim 7

The reovirus of any one of the preceding claims, wherein the reovirus is T3DATTC strain.

### Claim 8

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ3 protein comprising a substitution of lysine at position 198, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.

### Claim 9 (depends on 8)

The reovirus of claim 8, wherein the substitution at position 198 comprises the substitution K198G.

### Claim 10 (depends on 8, 9)

The reovirus of claim 8 or 9, wherein the reovirus further comprises a substitution of aspartic acid at position 229, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.

### Claim 11 (depends on 8, 9, 10)

The reovirus of any one of claims 8 to 10, wherein the substitution at position at position 229 comprises the substitution D229E.

### Claim 12 (depends on 8, 9, 10, 11)

The reovirus of any one of claims 8 to 11, wherein the reovirus is genetically modified to express a T3DPL reovirus σ1 protein comprising a substitution of serine at position 18, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.

### Claim 13 (depends on 12)

The reovirus of claim 12, wherein the substitution at position 18 in the T3DPL reovirus σ1 protein comprises the substitution S18I.

### Claim 14

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a mutation in the tail domain of the σ1 protein, wherein the mutation comprises a substitution of Leucine at position 28 or a substitution of serine at position 66 with reference to the amino acid sequence of wild type T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.

### Claim 15 (depends on 14)

The reovirus of claim 14, wherein the substitution is L28P.

### Claim 16 (depends on 14)

The reovirus of claim 14, wherein the substitution is S66I.

### Claim 17

A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a mutation in a FLAP domain, wherein the FLAP domain comprises amino acids 1023-1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9, wherein the reovirus expresses wild type T3DPL reovirus λ1 and λ3 proteins.

### Claim 18 (depends on 17)

The reovirus of claim 17, wherein the mutation is a substitution.

### Claim 19 (depends on 18)

The reovirus of claim 18, wherein the substitution comprises substitution of isoleucine at position 1274 or aparagine at position 1148 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9.

### Claim 20 (depends on 19)

The reovirus of claim 19, wherein the substitution at position 1274 is I1274T.

### Claim 21 (depends on 19)

The reovirus of claim 19, wherein the substitution at position 1274 is I1274M.

### Claim 22 (depends on 19)

The reovirus of claim 19, wherein the substitution at position 1148 is N1148S.

### Claim 23

A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274 or aparagine at position 1148 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9.

### Claim 24 (depends on 23)

The reovirus of claim 23, wherein the substitution at position 1274 is I1274T.

### Claim 25 (depends on 23)

The reovirus of claim 23, wherein the substitution at position 1274 is I1274M.

### Claim 26 (depends on 23)

The reovirus of claim 23, wherein the substitution at position 1148 is N1148S.

### Claim 27 (depends on 23, 24, 25, 26)

The reovirus of any one of claims 23-26, further genetically modified to express a T3DPL reovirus λ3 protein comprising a substitution of methionine at position 892 with reference to the amino acid sequence of wild type T3DPL reovirus λ3 protein set forth in SEQ ID NO:8.

### Claim 28 (depends on 27)

The reovirus of claim 27, wherein the substitution at position 892 is M892I.

### Claim 29 (depends on 27, 28)

The reovirus of any one of claims 27-28, further genetically modified to express a T3DPL reovirus σ3 protein comprising a substitution of histidine at position 230 with reference to the amino acid sequence of wild type T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.

### Claim 30 (depends on 29)

The reovirus of claim 29, wherein the substitution at position 230 is H230Q.

### Claim 31

A T3DPL reovirus genetically modified to express:
a T3DPL reovirus λ2 protein comprising a substitution of methionine at position 1101 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9;
a T3DPL reovirus λ3 protein comprising a substitution at position 892, wherein the numbering of the amino acid position is with reference to the amino acid sequence of wild type T3DPL reovirus λ3 protein set forth in SEQ ID NO:8; and
a T3DPL reovirus σ3 protein comprising a substitution at position 230, wherein the numbering of the amino acid position is with reference to the amino acid sequence of wild type T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.

### Claim 32 (depends on 31)

The reovirus of claim 31, wherein the substitution of methionine at position 1101 is M1101I.

### Claim 33 (depends on 31, 32)

The reovirus of claim 31 or 32, wherein the substitution at position 892 is M892I.

### Claim 34 (depends on 31, 32, 33)

The reovirus of any one of claims 31-33, wherein the substitution at position 230 is H230Q.

### Claim 35

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a mutation in the head domain, body domain, and/or tail domain, wherein:
the head domain extends from amino acid 296-455,
the body domain extends from amino acid 155-289,
the tail domain extends from amino acid 28-154, and
the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.

### Claim 36 (depends on 35)

The reovirus of claim 35, wherein the T3DPL reovirus σ1 protein comprises a mutation in the head domain of the σ1 protein.

### Claim 37 (depends on 36)

The reovirus of claim 36, wherein the mutation comprises a substitution.

### Claim 38 (depends on 37)

The reovirus of claim 37, wherein the substitution is at amino acid position 312.

### Claim 39 (depends on 38)

The reovirus of claim 38, wherein the substitution is N312R.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The reovirus of any one of claims 35-39, wherein the T3DPL reovirus σ1 protein comprises a mutation in the tail domain, wherein the mutation comprises a substitution at S66 and/or L28.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The reovirus of any one of claims 35-40, wherein the reovirus is genetically modified to express a T3DPL reovirus μ2 protein comprising a mutation at or adjacent amino acid position 112, 612, and/or 613, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus μ2 protein set forth in SEQ ID NO:5.

### Claim 42 (depends on 41)

The reovirus of claim 41, wherein the substitution is at position 612 or 613, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus μ2 protein set forth in SEQ ID NO:5.

### Claim 43 (depends on 42)

The reovirus of claim 42, wherein the substitution is at position 612 and is A612V.

### Claim 44 (depends on 42)

The reovirus of claim 42, wherein the substitution is at position 613 and is S613A.

### Claim 45 (depends on 35)

The reovirus of claim 35, wherein the T3DPL reovirus σ1 protein comprises a mutation in the body domain of the σ1 protein.

### Claim 46 (depends on 35)

The reovirus of claim 35, wherein the mutation is a substitution in the body domain of the σ1 protein.

### Claim 47 (depends on 46)

The reovirus of claim 46, wherein the substitution is at position 217 or 219.

### Claim 48 (depends on 47)

The reovirus of claim 47, wherein the substitution is at position 217.

### Claim 49 (depends on 48)

The reovirus of claim 48, wherein the substitution is at position 217 is Q217H.

### Claim 50 (depends on 47)

The reovirus of claim 47, wherein the substitution is at position 219.

### Claim 51 (depends on 50)

The reovirus of claim 50, wherein the substitution is at position 219 is R219S.

### Claim 52 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The reovirus of any one of claims 35-51, wherein the reovirus is further genetically modified to express a T3DPL reovirus λ2 protein comprising a mutation in a bridge domain, wherein the bridge domain comprises amino acids 386-433 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9.

### Claim 53 (depends on 52)

The reovirus of claim 52, wherein the mutation in the bridge domain comprises a substitution.

### Claim 54 (depends on 53)

The reovirus of claim 53, wherein the substitution is at amino acid position 408.

### Claim 55 (depends on 54)

The reovirus of claim 54, wherein the substitution at position 408 is D408N.

### Claim 56 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The reovirus of any one of claims 35-55, wherein the reovirus is genetically modified to express a T3DPL reovirus μ2 protein comprising a mutation in the a mutation at or adjacent amino acid position 112 and/or 613, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus μ2 protein set forth in SEQ ID NO:5.

### Claim 57 (depends on 56)

The reovirus of claim 56, wherein the T3DPL reovirus μ2 protein comprises a substitution at position 112.

### Claim 58 (depends on 56, 57)

The reovirus of claim 56 or 57, wherein the T3DPL reovirus μ2 protein comprises a substitution at position 613.

### Claim 59 (depends on 56, 57, 58)

The reovirus of any one of claims 56-58, wherein the T3DPL reovirus μ2 protein comprises the substitutions L112F and S613A.

### Claim 60 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The reovirus of any one of claims 35-51, wherein the reovirus is genetically modified to express a T3DPL reovirus σ1 protein comprising a mutation in the tail domain of the σ1 protein.

### Claim 61 (depends on 60)

The reovirus of claim 60, wherein the mutation is a substitution in the tail domain of the σ1 protein.

### Claim 62 (depends on 61)

The reovirus of claim 61, wherein the substitution is at position 114 of the σ1 protein.

### Claim 63 (depends on 62)

The reovirus of claim 62, wherein the substitution is T114P.

### Claim 64

A T3DPL reovirus genetically modified to express a T3DPL reovirus λ1 protein comprising a mutation at or adjacent the amino acid position 962 and/or 122 of the λ1 protein, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus λ1 protein set forth in SEQ ID NO:10.

### Claim 65 (depends on 64)

The reovirus of claim 64, wherein the mutation at or adjacent the amino acid position 962 and/or 122 of the λ1 protein comprises a substitution.

### Claim 66 (depends on 65)

The reovirus of claim 65, wherein the substitution is at amino acid position 962.

### Claim 67 (depends on 66)

The reovirus of claim 66, wherein the substitution is A962S.

### Claim 68

A T3DPL reovirus genetically modified to express:
a T3DPL reovirus λ1 protein comprising a mutation at or adjacent amino acid position 122 of the λ1 protein, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus λ1 protein set forth in SEQ ID NO:10;
T3DPL reovirus λ3 protein comprising a mutation at or adjacent amino acid position 972 of the λ3 protein, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus λ3 protein set forth in SEQ ID NO:8; and
T3DPL reovirus σ3 protein comprising a mutation at or adjacent amino acid position 64 of the σ3 protein, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.

### Claim 69 (depends on 68)

The reovirus of claim 68, wherein the mutation in the λ1 protein comprises a substitution at position 122.

### Claim 70 (depends on 69)

The reovirus of claim 69, wherein the mutation in the λ1 protein comprises the substitution at position 122 is Y122H.

### Claim 71 (depends on 68, 69, 70)

The reovirus of claim any one of claims 68-70, wherein the mutation in the λ3 protein comprises a substitution at position 972.

### Claim 72 (depends on 71)

The reovirus of claim 71, wherein the substitution at position 972 is Q972R.

### Claim 73 (depends on 68, 69, 70, 71, 72)

The reovirus of claim any one of claims 68-72, wherein the mutation in the σ3 protein comprises a substitution at position 64.

### Claim 74 (depends on 73)

The reovirus of claim 73, wherein the substitution at position 64 is K64E.

### Claim 75

A T3D reovirus genetically modified to express a mutant σ1 protein comprising a mutation in the body domain relative to a wild type σ1 protein, wherein the mutation in the body domain renders the mutant σ1 protein resistant to cleavage by the metalloprotease as compared to the wild type σ1 protein.

### Claim 76 (depends on 75)

The reovirus of claim 75, wherein mutation is present within amino acids 220-289 of the body domain of the σ1 protein.

### Claim 77 (depends on 75, 76)

The reovirus of claim 75 or 76, wherein mutation is present within amino acids 222-251 of the body domain of the σ1 protein.

### Claim 78 (depends on 75, 76, 77)

The reovirus of any one of claims 75-77, wherein mutation is present within a metalloprotease cleavage site in the body domain of the σ1 protein.

### Claim 79 (depends on 75, 76, 77, 78)

The reovirus of any one of claims 75-78, wherein mutation is present adjacent to a metalloprotease cleavage site in the body domain of the σ1 protein.

### Claim 80 (depends on 75)

The reovirus of claim 75, wherein the mutation comprises a substitution at position 249.

### Claim 81 (depends on 80)

The reovirus of claim 80, wherein the substitution is T249L or T249I.

### Claim 82

A T3DPL reovirus genetically modified to express T3DTD σ3 protein instead of the endogenous T3DPL σ3 protein.

### Claim 83

A T3DTD reovirus genetically modified to express T3DPL σ3 protein instead of the endogenous T3DTD σ3 protein.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A method for inducing cell death of a cancer cell, the method comprising contacting the cancer cell with the reovirus of any one of claims 1-83.

### Claim 85 (depends on 84)

The method of claim 84, wherein the cancer cell is in a subject.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A method for treating cancer in a subject, the method comprising administering a therapeutically effective amount of the reovirus of any one of claims 1-83 to the subject.

### Claim 87

A method for inducing a high interferon (IFN)-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD to the subject, wherein high IFN cytokines response comprises an IFN cytokines response that is higher than that induced by T3DPL.

### Claim 88

A method for inducing a low interferon (IFN)-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL to the subject, wherein the low IFN cytokines response comprises an IFN cytokines response that is lower than that induced by T3DTD.

### Claim 89 (depends on 87, 88)

The method of claim 87 or 88, wherein the IFN-dependent cytokines response comprises expression of one or more of Mx1, Cxcl10, Rsad2, Ccl4, Ifi44, and IL6.

### Claim 90

A method for inducing a high interferon (IFN)-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL to the subject, wherein the high IFN-independent, NF-κB-dependent cytokines response comprises a response that is higher than an IFN-independent, NF-κB-dependent cytokines response induced by T3DTD.

### Claim 91

A method for inducing a high interferon (IFN)-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD genetically modified to express a σ3 protein of T3DPL to the subject, wherein the high IFN-independent, NF-κB-dependent cytokines response comprises a response higher than an IFN-independent, NF-κB-dependent cytokines response induced by T3DTD expressing a T3DTD σ3 protein.

### Claim 92

A method for inducing a low IFN-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD to the subject, wherein the low IFN-independent, NF-κB-dependent cytokines response comprises a IFN-independent, NF-κB-dependent cytokines response that is lower than that induced by T3DPL.

### Claim 93

A method for inducing low IFN-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL genetically modified to express a σ3 protein of T3DTD to the subject, wherein the low IFN-independent, NF-κB-dependent cytokines response comprises a IFN-independent, NF-κB-dependent cytokines response that is lower than that induced by T3DPL expressing a T3DPL σ3 protein.

### Claim 94

The method of claim IFN-independent, NF-κB-dependent cytokines response comprises expression of one or more of Cxcl1, Csf2, Cxcl2, and Fas.

### Claim 95

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a substitution of serine at position 66 in the σ1 protein with reference to the amino acid sequence of wild type T3DPL reovirus σ1 protein set forth in SEQ ID NO:1 and to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9.

### Claim 96 (depends on 95)

The reovirus of claim 95, wherein the substitution in the σ1 protein is S66I.

### Claim 97 (depends on 95, 96)

The reovirus of claim 95 or 96, wherein the substitution at position 1274 in the λ2 protein is I1274T.

### Claim 98

A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9 and to express a T3DPL reovirus σ1 protein comprising a substitution at amino acid position 312, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.

### Claim 99 (depends on 98)

The reovirus of claim 98, wherein the substitution at position 1274 in the λ2 protein is I1274T.

### Claim 100 (depends on 98, 99)

The reovirus of claim 98 or 99, wherein the substitution in σ1 protein is N312R.

### Claim 101

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising the substitution S18I, a T3DPL reovirus σ3 protein comprising the substitution K64E, T3DPL reovirus μ2 protein comprising the substitution A612V, λ2 protein comprising the substitution I1274T, and λ1 protein comprising the substitution A962S.

### Claim 102

A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising the substitution R219Q, a T3DPL reovirus σ3 protein comprising the substitution K64E, T3DPL reovirus μ2 protein comprising the substitution A612V, λ2 protein comprising the substitution I1274T, and λ1 protein comprising the substitution A962S.

### Claim 103 (depends on 95, 96, 97, 98, 99, 100, 101, 102)

The T3DPL reovirus of any one of claims 95-102, further expressing a T3DPL reovirus σ3 protein comprising a substitution of T249.

### Claim 104 (depends on 103)

The T3DPL reovirus of claim 103, wherein the substitution is T249I.
